**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 65892

**Manuscript Type:** EDITORIAL

**Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype**

Jeong KY *et al.* Significance of PARP-1 inhibition targeting BRCAness pancreatic cancer

Keun-Yeong Jeong, Haejun Lee

**Keun-Yeong** Jeong, R&D Center, Metimedi Pharmaceuticals, Incheon 22006, South Korea

**Haejun Lee,** Department of Nuclear Medicine, Gil Medical Center, Incheon 21565, South Korea

**Author contributions:** Jeong KY conceived the contents and drafted the manuscript; Jeong KY and Lee H revised the manuscript; and all authors approved the final version of the article.

**Corresponding author: Keun-Yeong Jeong, PhD, Executive Vice President, Research Assistant Professor,** R&D Center, Metimedi Pharmaceuticals, 263 Central ro, Incheon 22006, South Korea. alvirus@naver.com

**Received:** March 17, 2021

**Revised:** April 20, 2021

**Accepted:** September 10, 2021

**Published online:** November 15, 2021

**Abstract**

The use of chemotherapeutic regimens for the treatment of pancreatic cancer is still limited because pancreatic cancer is usually diagnosed at an advanced stage as a refractory disease in which symptoms are difficult to recognize in the early stages. Furthermore, at advanced stages, there are important challenges to achieve clinical benefit and symptom resolution, even with the use of an expanded spectrum of anticancer drugs. Recently, a point of reduced susceptibility to conventional chemotherapies by breast cancer susceptibility gene (BRCA) mutations led to a new perspective for overcoming the resistance of pancreatic cancer within the framework of increased genome instability. Poly (ADP-Ribose) polymerase (PARP) -1 is an enzyme that can regulate intrinsic functions, such as response to DNA damage. Therefore, in an environment where germline mutations in BRCAs (BRCAness) inhibit homologous recombination in DNA damage, resulting in a lack of DNA damage response, a key role of PARP-1 for the adaptation of the genome instability could be further emphasized. Here, we summarized the key functional role of PARP-1 in genomic instability of pancreatic cancer with the BRCAness phenotype and listed clinical applications and outcomes of PARP-1 inhibitors to highlight the importance of targeting PARP-1 activity.

**Key Words:** Pancreatic cancer; BRCAness; Poly (ADP-Ribose) polymerase-1; PARylation; Poly (ADP-Ribose) polymerase-1 inhibitor

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Jeong KY, Lee H. Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype. *World J Gastrointest Oncol* 2021; 13(11): 1544-1550

**URL:** https://www.wjgnet.com/1948-5204/full/v13/i11/1544.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v13.i11.1544

**Core Tip:** The incidence of germline mutations of the breast cancer susceptibility gene (BRCA), defined as BRCAness, that can be targeted for pancreatic cancer is 9%-17%. Mutations in BRCAs are responsible for causing genetic instability and worsening the prognosis. Therefore, inhibition of poly (ADP-Ribose) polymerase-1 has emerged as a promising therapeutic target for BRCAness pancreatic cancer within the framework of an increase in genome instability.

**INTRODUCTION**

***Therapeutic perspectives in pancreatic cancer***

Pancreatic cancer is usually diagnosed at an advanced stage as a refractory disease in which symptoms are difficult to recognize in the early stages. The 5-year survival rate is extremely low (less than 9%), and about two-thirds of all patients with pancreatic cancer die within one year of diagnosis[1]. Furthermore, at advanced stages of the disease, there are major challenges to achieving clinical benefit and symptom resolution, even after expanding the range of anticancer drugs targeting pancreatic cancer, and to date, few options for treating pancreatic cancer have been proposed, such as gemcitabine alone, gemcitabine with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), or gemcitabine in combination with capecitabine, fluorouracil, leucovorin, irinotecan, and oxaliplatin[2]. The main cause of pancreatic carcinogenesis is genomic instability, and it is well established that cancer development is related to defects in DNA damage response[3]. Recent genome-wide studies have made great strides in identifying distinct subpopulations of pancreatic cancer constituent cells with unstable genomic properties due to mutations in the DNA repair gene[3,4]. Based on this background, there has been a focus on the high frequency of deleterious changes which lead to a truncated/faulty response to DNA damage in cancer cells. In particular, since breast cancer susceptibility genes (BRCA) mutations have been reported to decrease susceptibility to gemcitabine and platinum-based chemotherapy, a new perspective on the molecular mechanisms overcoming resistance in pancreatic cancer is required[5,6]. Therefore, the recent approach targeting poly (ADP-Ribose) polymerase (PARP) -1 has emerged as an encouraging therapeutic strategy for inhibiting the pathogenesis of BRCAness pancreatic cancer within the framework of an increase in genome instability[7].

**PARP-1 AND DNA DAMAGE RESPONSE IN PANCREATIC CANCER**

PARP-1 is an enzyme that can regulate the intrinsic functions of several cytoplasmic and nuclear proteins based on inducing poly (ADP-Ribose) synthesis[8]. In various cellular physiological functions led by PARP-1, the reaction to DNA damage is known as the most important biochemical function, and with its well-established crucial role in DNA damage repair, the upregulation of PARP-1 in cancer could lead to investigations into the potential for targeting this important enzyme[9]. PARP-1 comprises a multi-domain structure that shares the catalytic domain showing structural homology with other ADP-ribosyl transferases for DNA damage repair[10]. The N-terminal region contains a DNA-binding domain with three zinc fingers and an auto-modifying domain, and the C-terminal region comprises a protein interaction domain and a catalytic subdomain accountable for the poly ADP-ribosylation reaction[10,11]. The construction of such domains enables genetic relations by catalyzing the covalent attachment of poly-ADP-Ribose polymers to DNA repair proteins and other receptor proteins, including transcription factors and chromatin modulators. Based on these structural interactions, PARP-1 can mediate ADP-Ribose synthesis and attach it to acceptor proteins[10,11]. The PARP-1 signature motif includes an NAD+-binding site and comprises an acceptor of adenosine and the donor of nicotinamide wherein ADP-Ribose from NAD+ is transferred to target proteins for ADP-Ribose synthesis[11,12]. It is an integrative and dynamic biochemical process defined as poly ADP-ribosylation (PARylation), and the hypothesis has recently been established that the synthesis process is determined by following potential pathways[11,12]. PARP-1 catalyzes the transfer of ADP-Ribose units from NAD+ to compose the poly ADP-Ribose branches, which is negatively charged to several amino acid residues in PARP-1 or other receptor proteins[11]. Besides, poly (ADP-Ribose) synthesis is based on the attachment of ADP-Ribose to the 2'-OH end of the growing chain by sequentially adding the next ADP-Ribose residues to the end of the ADP-Ribose moiety[11]. The biochemical action of linking the long and negatively charged poly ADP-Ribose polymer to PARP-1 itself or a variety of acceptor proteins can be attributed to its primary function of repairing DNA damage during potential changes for cancer cell survival[11,13]. In DNA damage repair, PARP-1 and PARylation are universally involved in both single-strand and double-strand DNA damage repairs, such as base excision repair, homologous recombination (HR), and non-homologous end-joining (NHEJ)[14]. PARP-1 can functionally interact with X-ray repair cross-complementing protein 1, which plays a major role in signal pathways for single-strand DNA damage repair[14,15]. The BRCA1 C-terminus directly binds to the poly ADP-Ribose chain and mediates early recruitment of DNA repair proteins to DNA lesions[16]. Further, PARP-1 has been associated with HR-mediated repair and reactivation of stalled replication forks, thus promoting DNA replication for restarting stalled replication BRCA-dependent early double-strand DNA damage repair[17]. Interestingly, the role of PARP-1 in an environment where germline mutations in BRCAs inhibit the HR-mediated repair of DNA double-strand breaks, thus resulting in a deficiency in the DNA damage response, can be further emphasized[6,18].

**BRCANESS IN PANCREATIC CANCER AND PARP-1**

BRCAness is defined as a set of traits in which BRCA1 or BRCA2 mutation phenocopies result in a lack of double-strand DNA damage repair, and a tumor cell has an HR obstruction with a germline BRCA1 or BRCA2 deficiency[19]. The incidence of germline mutations of BRCAs that can be targeted for pancreatic cancer is estimated to be about 9%, but the incidence of these BRCA mutations (particularly BRCA2) in familial pancreatic cancer patients has increased to about 17%[20]. Mutations in BRCA are responsible for causing genetic instability and worsening prognosis. BRCAness leading to the phenotype of HR deficiency is an indispensable marker for recognizing an increase in the pancreatic cancer risk, and the sensor defect of double-strand DNA break is an error-prone repair pathway, such as NHEJ, which accumulates increased genomic instability. In this context, the HR deficiency by BRCAness may rely on a process of overcoming genetic instability that is reliant on PARP-1 activation[21]. As mentioned above, PARP-1 is an important nuclear enzyme in cellular homeostasis as it transforms various nuclear proteins by PARylation[8,11-14]. The key feature of PARP-1 is the DNA repair responding to DNA damage by targeting the histone core and linker histone proteins in the nucleus[22]. A serine group-binding ADP-ribose relies on a protein, histone PARylation factor 1 (HPF1), which has been identified as a key protein that controls DNA damage-induced PARylation and is responsible for adaptation to genomic instability[23,24]. Because PARP-1 continuously recruits DNA repair elements through PARylation in several receptor regions during genomic instability, HPF1 is used to regulate the excessive PARP-1 transformation to avoid apoptosis[14,15,24]. Taken together, PARP-1 activity and PARylation may play an important role in adapting to genomic instability in pancreatic cancer in a tumor microenvironment undergoing persistent genomic instability by BRCAness[13-15,20,21,23,24].

**CLINICAL STUDIES ON BRCANESS PANCREATIC CANCER BY PARP INHIBITORS**

BRCAness is unstable NHEJ-dependent and drives distinctive DNA repair systems creating specific genotypic and phenotypic features[19]. Therefore, it can be inferred that the sensitization of PARP-1 inhibitors has potential benefits for the treatment of BRCAness pancreatic cancer, and PARP inhibitors have recently emerged as a novel class of a targeted therapy specifically targeting BRCAness pancreatic cancer[18]. To date, five PARP inhibitors have drawn significant clinical results targeting BRCAness pancreatic cancer, and these agents bind to the catalytic domain of PARP and interfere with the base repair or suppress PARP synthesis[25]. Olaparib is first approved for the treatment of advanced ovarian cancer; however, presently, it is also being administered to patients having pancreatic cancer with BRCA mutations. Niraparib is a functionally selective inhibitor of PARP used for the treatment of advanced pancreatic cancer with BRCA mutations. Veliparib is being studied for its applicability to treating non-small-cell lung cancer and breast cancer with BRCA mutations, as well as advanced pancreatic cancer. Rucaparib is a small-molecule PARP inhibitor targeting germline BRCA-mutated pancreatic cancer. Talazoparib is an orally bioavailable PARP inhibitor with the potential antineoplastic activity that targets pancreatic cancer with BRCA mutations[25,26]. A pancreatic cancer olaparib ongoing (POLO) study was conducted on pancreatic cancer patients with BRCA mutations; these were the patients who did not show progression by platinum-based chemotherapy randomized to 92 patients in the phase 3 clinical trial. The results showed that median progression-free survival was increased to 31.3 mo in the olaparib group compared with 23.9 mo in the placebo group[27,28]. Another phase 2 trial has also demonstrated the efficacy of targeting metastatic pancreatic cancer with the germline BRCA mutant. A total of 32 patients was recruited, with one-two showing the partial response (PR), and eleven showing the stable disease (SD)[29,30]. Niraparib is undergoing a phase 2 clinical trial to test its safety and efficacy in patients with pancreatic cancer with HR deficiency, such as a BRCA mutation. This study is recruiting patients, and there are no interim reports[31,32]. The combination effect of cisplatin and gemcitabine with or without veliparib was reported by a phase 2 study in pancreatic cancer patients with germline BRCA mutations. A total number of 52 patients were enrolled in the trial and were randomly assigned to be treated with triple combination (gemcitabine, cisplatin, and veliparib) or double combination (gemcitabine and cisplatin). The objective response rate (ORR) in the former was higher at 74.1% compared with 65.2% in the latter[33,34]. A phase 2 trial of rucaparib in patients with pancreatic cancer with deleterious germline or somatic BRCA mutations was reported. In this study, 19 patients were treated, and the confirmed ORR was 11% (1 PR and 1 complete response). The disease control rate (PR or SD for above 12 wk) was 32% in all patients[35,36]. A dose-escalation, phase 1 study was organized to validate the antitumor activity of talazoparib. This study reported clinical benefits in 4 of the 13 patients with pancreatic cancer. The tumor response rate was 15% PR and 15% SD, and the median progression-free survival was 5.3 wk[37,38]. Table 1 presents a list of clinical trials for PARP inhibitors targeting BRCA mutant pancreatic cancer. However, while acknowledging the promising clinical outcomes of PARP-1 inhibitors, unexpected toxicity is an important concern to be considered. It can cause unacceptably high hematologic toxicity and adverse effects that are sporadically associated with acute myeloid leukemia. The combination of conventional chemotherapy, such as gemcitabine with veliparip or olaparip, was primarily associated with a marked increase in hematological toxicity above grade 3. Further, 40% of pancreatic cancer patients who received only olaparib showed gastrointestinal disorders, fatigue, and lethargy, as well as hematologic toxicity (Table 1)[25,39-42]. Therefore, potential solutions that can optimize treatment with sophisticated applied therapies through the development of new formulations are currently unmet medical needs.

**CONCLUSION**

The possibility that PARP-1 inhibitors effectively improve the prognosis by targeting pancreatic cancer with the BRCAness phenotype appears to deserve scientific attention, and the accumulation of such possibilities could be a key point in understanding whether PARP inhibitors can be used as a major therapeutic strategy as a single therapeutic agent or in combination with existing DNA damage agents to overcome resistance.

**REFERENCES**

1 **Wolfgang CL**, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. *CA Cancer J Clin* 2013; **63**: 318-348 [PMID: 23856911 DOI: 10.3322/caac.21190]

2 **Lambert A**, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. *Ther Adv Med Oncol* 2019; **11**: 1758835919875568 [PMID: 31598142 DOI: 10.1177/1758835919875568]

3 **Sahin IH**, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. *Expert Rev Gastroenterol Hepatol* 2016; **10**: 893-905 [PMID: 26881472 DOI: 10.1586/17474124.2016.1153424]

4 **Jäkel C**, Bergmann F, Toth R, Assenov Y, van der Duin D, Strobel O, Hank T, Klöppel G, Dorrell C, Grompe M, Moss J, Dor Y, Schirmacher P, Plass C, Popanda O, Schmezer P. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. *Nat Commun* 2017; **8**: 1323 [PMID: 29109526 DOI: 10.1038/s41467-017-01118-x]

5 **Mylavarapu S**, Das A, Roy M. Role of BRCA Mutations in the Modulation of Response to Platinum Therapy. *Front Oncol* 2018; **8**: 16 [PMID: 29459887 DOI: 10.3389/fonc.2018.00016]

6 **Patel M**, Nowsheen S, Maraboyina S, Xia F. The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. *Cell Biosci* 2020; **10**: 35 [PMID: 32180937 DOI: 10.1186/s13578-020-00390-7]

7 **Gupta M**, Iyer R, Fountzilas C. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. *Cancers (Basel)* 2019; **11** [PMID: 31835379 DOI: 10.3390/cancers11121980]

8 **Kim MY**, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. *Genes Dev* 2005; **19**: 1951-1967 [PMID: 16140981 DOI: 10.1101/gad.1331805]

9 **Ray Chaudhuri A**, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. *Nat Rev Mol Cell Biol* 2017; **18**: 610-621 [PMID: 28676700 DOI: 10.1038/nrm.2017.53]

10 **Nguewa PA**, Fuertes MA, Valladares B, Alonso C, Pérez JM. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. *Prog Biophys Mol Biol* 2005; **88**: 143-172 [PMID: 15561303 DOI: 10.1016/j.pbiomolbio.2004.01.001]

11 **Alemasova EE**, Lavrik OI. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. *Nucleic Acids Res* 2019; **47**: 3811-3827 [PMID: 30799503 DOI: 10.1093/nar/gkz120]

12 **Ryu KW**, Kim DS, Kraus WL. New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases. *Chem Rev* 2015; **115**: 2453-2481 [PMID: 25575290 DOI: 10.1021/cr5004248]

13 **Kamaletdinova T**, Fanaei-Kahrani Z, Wang ZQ. The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers. *Cells* 2019; **8** [PMID: 31842403 DOI: 10.3390/cells8121625]

14 **Wei H**, Yu X. Functions of PARylation in DNA Damage Repair Pathways. *Genomics Proteomics Bioinformatics* 2016; **14**: 131-139 [PMID: 27240471 DOI: 10.1016/j.gpb.2016.05.001]

15 **Ko HL**, Ren EC. Functional Aspects of PARP1 in DNA Repair and Transcription. *Biomolecules* 2012; **2**: 524-548 [PMID: 24970148 DOI: 10.3390/biom2040524]

16 **Li M**, Yu X. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. *Cancer Cell* 2013; **23**: 693-704 [PMID: 23680151 DOI: 10.1016/j.ccr.2013.03.025]

17 **Bryant HE**, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, Johansson F, Fernandez S, McGlynn P, Helleday T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. *EMBO J* 2009; **28**: 2601-2615 [PMID: 19629035 DOI: 10.1038/emboj.2009.206]

18 **Pant S**, Maitra A, Yap TA. PARP inhibition - opportunities in pancreatic cancer. *Nat Rev Clin Oncol* 2019; **16**: 595-596 [PMID: 31332344 DOI: 10.1038/s41571-019-0257-6]

19 **Turner N**, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. *Nat Rev Cancer* 2004; **4**: 814-819 [PMID: 15510162 DOI: 10.1038/nrc1457]

20 **Wong W**, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. *Cancer Manag Res* 2020; **12**: 2731-2742 [PMID: 32368150 DOI: 10.2147/CMAR.S211151]

21 **Perkhofer L**, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. *Gut* 2021; **70**: 606-617 [PMID: 32855305 DOI: 10.1136/gutjnl-2019-319984]

22 **Li Z**, Li Y, Tang M, Peng B, Lu X, Yang Q, Zhu Q, Hou T, Li M, Liu C, Wang L, Xu X, Zhao Y, Wang H, Yang Y, Zhu WG. Destabilization of linker histone H1.2 is essential for ATM activation and DNA damage repair. *Cell Res* 2018; **28**: 756-770 [PMID: 29844578 DOI: 10.1038/s41422-018-0048-0]

23 **Sun FH**, Zhao P, Zhang N, Kong LL, Wong CCL, Yun CH. HPF1 remodels the active site of PARP1 to enable the serine ADP-ribosylation of histones. *Nat Commun* 2021; **12**: 1028 [PMID: 33589610 DOI: 10.1038/s41467-021-21302-4]

24 **Bonfiglio JJ**, Fontana P, Zhang Q, Colby T, Gibbs-Seymour I, Atanassov I, Bartlett E, Zaja R, Ahel I, Matic I. Serine ADP-Ribosylation Depends on HPF1. *Mol Cell* 2017; **65**: 932-940.e6 [PMID: 28190768 DOI: 10.1016/j.molcel.2017.01.003]

25 **Zhu H**, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. *Mol Cancer* 2020; **19**: 49 [PMID: 32122376 DOI: 10.1186/s12943-020-01167-9]

26 **Kasi A**, Al-Jumayli M, Park R, Baranda J, Sun W. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. *J Pancreat Cancer* 2020; **6**: 107-115 [PMID: 33376937 DOI: 10.1089/pancan.2020.0010]

27 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy. [cited 10 March 2021]. Available from: https://ClinicalTrials.gov/show/NCT02184195

28 **Golan T**, Hammel P, Reni M, Cutsem EV, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh D-Y, Reinacher-Schick AC, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui K, Schlienger K, Locker GY, Kindler HL. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. *J Clin Oncol* 2021; **39**: 378-378 [DOI: 10.1200/JCO.2021.39.3\_suppl.378]

29 Olaparib in Treating Patients With Stage IV Pancreatic Cancer. [cited 10 March 2021]. Available from: https://ClinicalTrials.gov/show/NCT02677038

30 **Golan T**, Varadhachary GR, Sela T, Fogelman DR, Halperin N, Shroff RT, Halparin S, Xiao L, Aderka D, Maitra A, Ackerstein A, Wolff RA, Shacham-Shmueli E, Javle MM. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. *J Clin Oncol* 2018; **36**: 297-297 [DOI: 10.1200/JCO.2018.36.4\_suppl.297]

31 Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial. [cited 10 March 2021]. Available from: https://ClinicalTrials.gov/show/NCT03553004

32 **Kasi A**, Chalise P, Williamson SK, Baranda JC, Sun W, Al-Rajabi RMdT, Saeed A, Kumer S, Schmitt T, Foster C, Pessetto ZY, Witek MA, Soper SA, Godwin AK. Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial. *J Clin Oncol* 2019; **37**: TPS4168-TPS4168 [DOI: 10.1200/JCO.2019.37.15\_suppl.TPS4168]

33 Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer. [cited 10 March 2021]. Available from: https://ClinicalTrials.gov/show/NCT01585805

34 **Lowery MA**, Kelsen DP, Smith SC, Moore M, Kindler HL, Golan T, Segal A, Hollywood E, Maynard H, Capanu M, Moynahan ME, Fusco A, Stadler ZK, Do KG, Chen AP, Yu KH, Tang LH, O'Reilly EM. Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC). *J Clin Oncol* 2015; **33**: 358-358 [DOI: 10.1200/jco.2015.33.3\_suppl.358]

35 A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. [cited 10 March 2021]. Available from: https://ClinicalTrials.gov/show/NCT02042378

36 **Domchek SM**, Hendifar AE, McWilliams RR, Geva R, Epelbaum R, Biankin A, Vonderheide RH, Wolff RA, Alberts SR, Giordano H, Goble S, Lin KK, Shroff RT. RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation. *J Clin Oncol* 2016; **34**: 4110-4110 [DOI: 10.1200/JCO.2016.34.15\_suppl.4110]

37 Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors. [cited 10 March 2021]. Available from: https://ClinicalTrials.gov/show/NCT01286987

38 **Wainberg ZA**, Rafii S, Ramanathan RK, Mina LA, Byers LA, Chugh R, Goldman JW, Sachdev JC, Matei DE, Wheler JJ, Henshaw JW, Zhang C, Gallant G, Bono JSD. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. *J Clin Oncol* 2014; **32**: 7522-7522 [DOI: 10.1200/jco.2014.32.15\_suppl.7522]

39 **Tuli R**, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. *EBioMedicine* 2019; **40**: 375-381 [PMID: 30635165 DOI: 10.1016/j.ebiom.2018.12.060]

40 **Kristeleit R**, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline *BRCA1/2*-Mutated Ovarian Carcinoma or Other Solid Tumors. *Clin Cancer Res* 2017; **23**: 4095-4106 [PMID: 28264872 DOI: 10.1158/1078-0432.CCR-16-2796]

41 **Shroff RT**, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious *BRCA* Mutation. *JCO Precis Oncol* 2018; **2018** [PMID: 30051098 DOI: 10.1200/PO.17.00316]

42 **de Bono J**, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline *BRCA1/2* Mutations and Selected Sporadic Cancers. *Cancer Discov* 2017; **7**: 620-629 [PMID: 28242752 DOI: 10.1158/2159-8290.CD-16-1250]

**Footnotes**

**Conflict-of-interest statement:** We have no conflict of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review started:** March 17, 2021

**First decision:** April 19, 2021

**Article in press:** September 10, 2021

**Specialty type:** Oncology

**Country/Territory of origin:** South Korea

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Wang T **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Guo X

**Table 1 Clinical trials of Poly (ADP-Ribose) polymerase-1 inhibitor for the treatment of breast cancer susceptibility gene mutant pancreatic cancer**

|  |  |  |  |
| --- | --- | --- | --- |
| **Drugs** | **Trial ID** | **Stage** | **Outcomes** |
| Olaparib | NCT02184195 | Phase II | Median OS (drug/placebo): 19.0/19.2 mo; Median PFS (drug/placebo): 16.9/9.3 mo; Toxicity: Grade ≥ 3 anemia, hyperglycemia, pain |
| Olaparib | NCT02677038 | Phase II | 5 SD, 12 PD in Israel; 2 PR, 6 SD, 3 PD in United States; PFS: 14 wk in Israel; 24.7 wk in United States; Toxicity: grade 1-2 anemia, fatigue, nausea |
| Niraparip | NCT03553004 | Phase II | No results posted |
| Veliparib | NCT01585805 | Phase II | 4 SD, 10 PD; Median PFS: 52 d; Toxicity: Grade 3 fatigue, hematologic, nausea |
| Rucaparib | NCT02042378 | Phase II | ≥ 2 prior chemotherapy: 1 PR, 1 CR; 1 prior chemotherapy: 4 SD, 9 PD; Toxicity: Grade ≥ 3 anemia, thrombocytopenia, fatigue |
| Talazoparib | NCT01286987 | Phase I | 2 PR, 2 SD, 6 PD; Median PFS: 5.3 wk; Toxicity: Hyperbilirubinemia, fever, bacteremia |

OS: Overall survival; PFS: Progression-free survival; SD: Stable disease; PD: Progression disease; PR: Partial response; CR: Complete response.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**